GenMark Diagnostics Inc. (NASDAQ:GNMK)’s share price traded down 6.1% during trading on Monday . The company traded as low as $9.88 and last traded at $10.00, with a volume of 178,822 shares. The stock had previously closed at $10.65.

A number of equities analysts have recently commented on the stock. Zacks Investment Research raised shares of GenMark Diagnostics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a report on Tuesday. Canaccord Genuity reaffirmed a “buy” rating and set a $13.00 target price on shares of GenMark Diagnostics in a report on Friday, July 29th. JPMorgan Chase & Co. increased their target price on shares of GenMark Diagnostics from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Friday, July 29th. Finally, Needham & Company LLC initiated coverage on shares of GenMark Diagnostics in a report on Friday, June 17th. They set a “buy” rating and a $13.00 target price on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $10.39.

The stock’s market capitalization is $409.72 million. The firm’s 50 day moving average is $9.33 and its 200 day moving average is $6.74.

GenMark Diagnostics (NASDAQ:GNMK) last released its earnings results on Thursday, July 28th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. During the same period last year, the firm posted ($0.29) EPS. The company earned $12.50 million during the quarter, compared to analysts’ expectations of $9.62 million. GenMark Diagnostics’s quarterly revenue was up 63.6% compared to the same quarter last year. Equities analysts expect that GenMark Diagnostics Inc. will post ($1.17) earnings per share for the current fiscal year.

Other institutional investors recently added to or reduced their stakes in the company. Jennison Associates LLC increased its position in GenMark Diagnostics by 7.3% in the fourth quarter. Jennison Associates LLC now owns 3,144,434 shares of the company’s stock valued at $24,401,000 after buying an additional 214,822 shares during the period. I.G. Investment Management LTD. increased its position in GenMark Diagnostics by 0.7% in the fourth quarter. I.G. Investment Management LTD. now owns 134,589 shares of the company’s stock valued at $1,044,000 after buying an additional 978 shares during the period. Finally, Morgan Stanley increased its position in GenMark Diagnostics by 10,433.5% in the fourth quarter. Morgan Stanley now owns 1,338,286 shares of the company’s stock valued at $10,385,000 after buying an additional 1,325,581 shares during the period.

GenMark Diagnostics, Inc (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.